Regarding tariffs, Barclays estimates the financial impact of existing and potential duties on Sandoz at $25-$35 million in 2025, with an annualized impact of $35-$50 million. If the European Union ...

Patients with diabetic macular edema previously treated with a ranibizumab biosimilar in India experience comparable safety and efficacy after being switched to another ranibizumab biosimilar, ...

The US Food and Drug Administration (FDA) approved Sandoz’s Enzeevu (aflibercept-abzv), the drugmaker’s biosimilar for wet age-related macular degeneration (AMD), in August 2024. Despite ...

Growth in the US has been driven by the acquisition of Cimerli, a Lucentis biosimilar. Aflibercept (Enzeevu and Wyost/Jubbonti) and ustekinumab (Pyzchiva) are also anticipated to launch in 2025 in the ...